DB00408ApprovedInvestigationalSmall moleculeAntipsychotic Agents (First Generation [Typical])Dopamine D2 Receptor Antagonists
Loxapine is a antipsychotic used for the treatment of schizophrenia.
- Mechanism
- Curator reviewed
Loxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior.
- Primary indication
- For the management of the manifestations of psychotic disorders such as schizophreniaCurator reviewed · 3 structured indications
- Formula / weight
- C18H18ClN3O · 327.808 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1988 · European Union, 2016
- Also known as
- Oxilapine
- Code names
- AZ-004 · BRN 0626753 · CL-62362 · CL 71563 · HF 3170 · LW 3170 · S 805 · SUM-3170
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
XJGVXQDUIWGIRW-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2What you can answer from here — as of September 23, 2026
33Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Loxapine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account